• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

近年来透明细胞腺癌的发病率和生存结局的变化趋势:一项 SEER 分析。

Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis.

机构信息

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.

Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.

出版信息

Front Endocrinol (Lausanne). 2022 Feb 24;13:762589. doi: 10.3389/fendo.2022.762589. eCollection 2022.

DOI:10.3389/fendo.2022.762589
PMID:35282450
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8907425/
Abstract

BACKGROUND

Clear cell adenocarcinoma (CCA) is considered a relatively rare tumor with a glycogen-rich phenotype. The prognosis of CCA patients is unclear. In this study, recent trends in the epidemiological and prognostic factors of CCA were comprehensively investigated.

METHODS

Patients with CCA from years 2000 to 2016 were identified from the Surveillance, Epidemiological, and End Results (SEER) database. Relevant population data were used to analyze the rates age-adjusted incidence, age-standardized 3-year and 5-year relative survivals, and overall survival (OS).

RESULTS

The age-adjusted incidence of CCA increased 2.7-fold from the year 2000 (3.3/100,000) to 2016 (8.8/100,000). This increase occurred across all ages, races, stages, and grades. Of all these subgroups, the increase was largest in the grade IV group. The age-standardized 3-year and 5-year relative survivals increased during this study period, rising by 9.1% and 9.5% from 2000 to 2011, respectively. Among all the stages and grades, the relative survival increase was greatest in the grade IV group. According to multivariate analysis of all CCA patients, predictors of OS were: age, gender, year of diagnosis, marital status, race, grade, stage, and primary tumor site ( < 0.001). The OS of all CCA patients during the period 2008 to 2016 was significantly higher than that from 2000 to 2007 ( < 0.001).

CONCLUSIONS

The incidence of CCA and survival of these patients improved over time. In particular, the highest increases were reported for grade IV CCA, which may be due to an earlier diagnosis and improved treatment.

摘要

背景

透明细胞腺癌(CCA)被认为是一种相对罕见的肿瘤,具有丰富糖原的表型。CCA 患者的预后尚不清楚。本研究综合调查了 CCA 的流行病学和预后因素的最新趋势。

方法

从监测、流行病学和最终结果(SEER)数据库中确定了 2000 年至 2016 年期间的 CCA 患者。使用相关的人口数据来分析年龄调整发病率、年龄标准化 3 年和 5 年相对生存率以及总生存率(OS)。

结果

CCA 的年龄调整发病率从 2000 年的 3.3/100,000 增加到 2016 年的 8.8/100,000,增加了 2.7 倍。这种增加发生在所有年龄段、种族、分期和分级中。在所有这些亚组中,IV 级组的增加最大。在研究期间,年龄标准化的 3 年和 5 年相对生存率有所提高,分别从 2000 年到 2011 年提高了 9.1%和 9.5%。在所有分期和分级中,IV 级组的相对生存率提高最大。根据所有 CCA 患者的多变量分析,OS 的预测因素是:年龄、性别、诊断年份、婚姻状况、种族、分级、分期和原发肿瘤部位(<0.001)。2008 年至 2016 年期间所有 CCA 患者的 OS 明显高于 2000 年至 2007 年(<0.001)。

结论

CCA 的发病率和患者的生存率随时间推移而提高。特别是 IV 级 CCA 的增加幅度最大,这可能是由于更早的诊断和改善的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/e5a9e4b8e08d/fendo-13-762589-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/fcfd6272ce71/fendo-13-762589-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/a19b7c45ca3a/fendo-13-762589-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/d875a180fdfe/fendo-13-762589-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/30eda719c85b/fendo-13-762589-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/e5a9e4b8e08d/fendo-13-762589-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/fcfd6272ce71/fendo-13-762589-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/a19b7c45ca3a/fendo-13-762589-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/d875a180fdfe/fendo-13-762589-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/30eda719c85b/fendo-13-762589-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cdc/8907425/e5a9e4b8e08d/fendo-13-762589-g005.jpg

相似文献

1
Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis.近年来透明细胞腺癌的发病率和生存结局的变化趋势:一项 SEER 分析。
Front Endocrinol (Lausanne). 2022 Feb 24;13:762589. doi: 10.3389/fendo.2022.762589. eCollection 2022.
2
Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States.美国胆管癌发病率的变化趋势及影响生存的因素。
J Natl Compr Canc Netw. 2018 Apr;16(4):370-376. doi: 10.6004/jnccn.2017.7056.
3
Clear cell adenocarcinoma of the lung: a SEER analysis.肺透明细胞腺癌:一项监测、流行病学和最终结果(SEER)分析
Transl Lung Cancer Res. 2019 Apr;8(2):187-191. doi: 10.21037/tlcr.2018.10.13.
4
Clear Cell Adenocarcinoma of the Urinary Bladder Is a Glycogen-Rich Tumor with Poorer Prognosis.膀胱透明细胞腺癌是一种富含糖原且预后较差的肿瘤。
J Clin Med. 2020 Jan 3;9(1):138. doi: 10.3390/jcm9010138.
5
Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States.美国 1947 年至 1971 年出生的女性中,宫颈和阴道透明细胞腺癌的发病率较高。
Cancer Causes Control. 2012 Jan;23(1):207-11. doi: 10.1007/s10552-011-9855-z. Epub 2011 Oct 21.
6
20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes: .按年龄、性别、种族、分期、分级、队列入组时间、疾病持续时间及选定的ICD-O-3肿瘤学表型对胃癌进行的20年生存和死亡率比较:
J Insur Med. 2019;48(1):5-23. doi: 10.17849/insm-48-1-1-19.1. Epub 2019 Oct 14.
7
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).浆细胞骨髓瘤——按年龄、性别、种族、分期、队列入组时间和疾病持续时间对三种浆细胞骨髓瘤国际疾病分类肿瘤学形态进行的20年生存和死亡率比较:对1973 - 2014年诊断的111,041例病例的系统评价:(监测、流行病学和最终结果*统计8.3.4)
J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22.
8
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.美国神经内分泌肿瘤患者的发病率、患病率和生存结局趋势。
JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.
9
Cholangiocarcinoma Among Children and Adolescents: A Review of the Literature and Surveillance, Epidemiology, and End Results Program Database Analysis.儿童和青少年胆管癌:文献综述及监测、流行病学和最终结果计划数据库分析
J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):e12-e18. doi: 10.1097/MPG.0000000000001749.
10
Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up.二乙基己烯雌酚相关阴道和宫颈透明细胞腺癌的发病率和风险:40 年随访后更新。
Gynecol Oncol. 2017 Sep;146(3):566-571. doi: 10.1016/j.ygyno.2017.06.028. Epub 2017 Jul 6.

引用本文的文献

1
Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer.肿瘤内微生物群衍生的丁酸酯促进结直肠癌的化疗耐药性。
Front Pharmacol. 2025 Jan 15;15:1510851. doi: 10.3389/fphar.2024.1510851. eCollection 2024.
2
Primary clear cell adenocarcinoma of the lung: a national analysis.原发性肺透明细胞腺癌:一项全国性分析。
J Thorac Dis. 2023 Aug 31;15(8):4248-4261. doi: 10.21037/jtd-23-76. Epub 2023 Aug 28.
3
Factors That Affect Survival Outcomes in Patients with Endometrial Clear Cell Carcinoma.影响子宫内膜透明细胞癌患者生存结局的因素

本文引用的文献

1
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.帕博利珠单抗联合贝伐珠单抗治疗转移性肾细胞癌的 Ib/II 期临床研究:BTCRC-GU14-003。
J Clin Oncol. 2020 Apr 10;38(11):1138-1145. doi: 10.1200/JCO.19.02394. Epub 2020 Feb 25.
2
Clear Cell Adenocarcinoma of the Urinary Bladder Is a Glycogen-Rich Tumor with Poorer Prognosis.膀胱透明细胞腺癌是一种富含糖原且预后较差的肿瘤。
J Clin Med. 2020 Jan 3;9(1):138. doi: 10.3390/jcm9010138.
3
Absence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor Growth.
J Clin Med. 2022 Nov 24;11(23):6931. doi: 10.3390/jcm11236931.
HIF1A 缺失导致肝醣累积和引发炎症反应,从而促进胰脏肿瘤生长。
Cancer Res. 2019 Nov 15;79(22):5839-5848. doi: 10.1158/0008-5472.CAN-18-2994. Epub 2019 Oct 4.
4
A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.一种依赖 GPX4 的癌细胞状态是透明细胞形态的基础,并赋予了对铁死亡的敏感性。
Nat Commun. 2019 Apr 8;10(1):1617. doi: 10.1038/s41467-019-09277-9.
5
Clinical Features, Survival and Prognostic Factors of Glycogen-Rich Clear Cell Carcinoma (GRCC) of the Breast in the U.S. Population.美国人群中乳腺富含糖原透明细胞癌(GRCC)的临床特征、生存情况及预后因素
J Clin Med. 2019 Feb 14;8(2):246. doi: 10.3390/jcm8020246.
6
Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.立体定向体部放疗在寡转移肾细胞癌治疗中的作用。
J Urol. 2019 Jan;201(1):70-75. doi: 10.1016/j.juro.2018.08.049.
7
Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study.新诊断肾细胞癌骨转移的发生率及其发生发展和预后的相关因素:一项基于人群的研究
Cancer Manag Res. 2018 Aug 28;10:2935-2944. doi: 10.2147/CMAR.S170083. eCollection 2018.
8
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会关于同步转移性透明细胞肾细胞癌患者细胞减瘤性肾切除术的指南。
Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.
9
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.成纤维细胞动员肿瘤细胞糖原促进增殖和转移。
Cell Metab. 2019 Jan 8;29(1):141-155.e9. doi: 10.1016/j.cmet.2018.08.007. Epub 2018 Aug 30.
10
Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.卵巢癌远处转移部位与总生存期:一项 1481 例患者的研究。
Gynecol Oncol. 2018 Sep;150(3):460-465. doi: 10.1016/j.ygyno.2018.06.022. Epub 2018 Jul 9.